Expertise in
5
conditions

Jen-yu S. Hung

100 Tzyou Road, 807, 
Kaohsiung, KHQ, TW 
Expertise in
5
conditions
100 Tzyou Road, 807, 
Kaohsiung, KHQ, TW 

Overview

Jen-yu Hung practices practicing medicine in Kaohsiung, Taiwan.

Hung is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Lung Adenocarcinoma, Lung Cancer, EGFR Positive Lung Cancer, Squamous Cell Lung Carcinoma, and Tissue Biopsy.

They are actively involved in clinical research, co-authoring 106 peer reviewed articles and participating in 2 clinical trials.

Locations

100 Tzyou Road, 807, Kaohsiung, KHQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brigatinib, Alectinib
Study Phase: Phase 3
View 1 Less Clinical Trial

106 Total Publications

Surgical strategy and prognostic factors in very elderly (≥ 75 Years) patients with stage I NSCLC: insights from a propensity score-matched analysis.
Surgical strategy and prognostic factors in very elderly (≥ 75 Years) patients with stage I NSCLC: insights from a propensity score-matched analysis.
Journal: BMC pulmonary medicine
Published: December 07, 2025

Frequently Asked Questions about Jen-yu S. Hung

Is Jen-yu S. Hung a top-rated expert for Lung Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Jen-yu S. Hung is classified as an Distinguished expert for Lung Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jen-yu S. Hung participate in research or clinical trials?

Yes. Jen-yu S. Hung has published 106 articles and abstracts on conditions like Lung Adenocarcinoma. You can view a list of Jen-yu S. Hung's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hung's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile